Shuanglan Xu

818 citations
42 papers · 501 indexed · h-index 12
Topics
Pulmonary Hypertension Research and Treatments (9 papers)Cancer-related molecular mechanisms research (8 papers)MicroRNA in disease regulation (7 papers)

In The Last Decade

Shuanglan Xu

38 papers receiving 493 citations

Peers

Shuanglan Xu
Comparison fields: 5 of 89
  • Pulmonary and Respiratory Medicine 179
  • Molecular Biology 157
  • Oncology 141
  • Cancer Research 109
  • Surgery 82
Replace Hirokazu Urushiyama with:
Hirokazu Urushiyama Japan
Honglin Zhao China
Matthieu Sarabi France
Rosanne Rouf United States
Wan Kyu Eo South Korea
Anying Cheng China
Xuefeng Yu China
Kota Nishihama Japan
Gadi Shlomai Israel
Jinrui Yang China
Shuanglan Xu relative to Hirokazu Urushiyama Japan Hirokazu Urushiyama's profile →
Citations per field
00.5×3.1×
Hirokazu Urushiyama · 1×
Citations per year

Countries citing papers authored by Shuanglan Xu

Since Specialization
Citations

This map shows the geographic impact of Shuanglan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuanglan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuanglan Xu more than expected).

Fields of papers citing papers by Shuanglan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuanglan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuanglan Xu. The network helps show where Shuanglan Xu may publish in the future.

Co-authorship network of co-authors of Shuanglan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Shuanglan Xu. A scholar is included among the top collaborators of Shuanglan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuanglan Xu. Shuanglan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 1
3 0
4 1
5 0
6 5
7 7
8 0
9 9
10 1
11 6
12 2
13 30
14 9
15 11
16 17
17 24
18 6
19 4
20 47

About Shuanglan Xu

Shuanglan Xu is a scholar working on Internal Medicine, Cancer Research and Pulmonary and Respiratory Medicine, having authored 42 papers that have together received 501 indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (9 papers), Cancer-related molecular mechanisms research (8 papers) and MicroRNA in disease regulation (7 papers). The work is most often cited by research in Cancer Research (109 citations), Pulmonary and Respiratory Medicine (179 citations) and Oncology (141 citations). Shuanglan Xu has collaborated with scholars based in China, United States and Ireland. Frequent co-authors include Jiao Yang, Xiqian Xing, Yun Zhu, Jianping Liu, Zhaowei Teng, Yunlong Dong, Yishu Deng, Chunfang Zhang, Jun Zhang and Jiao Zhou. Their work appears in journals such as PLoS ONE, Scientific Reports and International Journal of Pharmaceutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026